| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-23T01:06:33Z |
Gold nanoparticles conjugates-amplified aptamer immunosensing screen-printed carbon electrode strips for thrombin detection
|
Yeh F.-Y.; Liu T.-Y.; Tseng I.-H.; CHUNG WEI YANG; Lu L.-C.; Lin C.-S. |
| 臺大學術典藏 |
2021-08-23T01:06:31Z |
Imbalanced plasma ace and ace2 level in the uremic patients with cardiovascular diseases and its change during a single hemodialysis session
|
CHUNG WEI YANG; Lu L.-C.; Chang C.-C.; Cho C.-C.; Hsieh W.-Y.; Tsai C.-H.; Lin Y.-C.; Lin C.-S. |
| 臺大學術典藏 |
2021-08-23T01:06:31Z |
Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis
|
Lu L.-C.; CHUNG WEI YANG; Hsieh W.-Y.; Chuang W.-H.; Lin Y.-C.; Lin C.-S. |
| 臺大學術典藏 |
2021-08-23T01:06:28Z |
Renal chymase-dependent pathway for angiotensin II formation mediated acute kidney injury in a mouse model of aristolochic acid I-induced acute nephropathy
|
Hsieh W.-Y.; Chang T.-H.; Chang H.-F.; Chuang W.-H.; Lu L.-C.; CHUNG WEI YANG; Lin C.-S.; Chang C.-C. |
| 臺大學術典藏 |
2021-08-18T07:39:05Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; JHE-CYUAN GUO; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T06:55:42Z |
A dengue vector surveillance by humrn population-stratified ovitrap survey for aedes (Diptera: Culicidae) adult and egollections in high dengue-risk areas of Taiwan
|
Wu H.-H.; Wang C.-Y.; Teng H.-J.; Lin C.; Lu L.-C.; Jian S.-W.; Chang N.-T.; Wen T.-H.; Wu J.-W.; DING-PING LIU; Lin L.-J.; Norris D.E.; Wu H.-S. |
| 臺大學術典藏 |
2021-08-11T03:46:45Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:43Z |
Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma
|
Lu L.-C.; Shao Y.-Y.; Kuo R.N.C.; ZHONG-ZHE LIN; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2021-08-11T03:46:37Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:36Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; ZHONG-ZHE LIN; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-03T07:10:53Z |
Solving the deficit of cancer pain management skills by education programs
|
YU-YUN SHAO; Lin W.-Y.; Lin C.-P.; Lu L.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2021-07-23T07:49:43Z |
Solving the deficit of cancer pain management skills by education programs
|
Shao Y.-Y.; WEN-YING LIN; Lin C.-P.; Lu L.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2021-07-12T08:46:25Z |
�]-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma
|
Lu L.-C.; Shao Y.-Y.; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; HSIANG-FONG KAO; Ma Y.-Y.; Yen F.-C.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:48Z |
Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study
|
Lu L.-C.; PEI-JER CHEN; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-19T01:54:20Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
TSUNG-HAO LIU; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-19T01:54:20Z |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Lu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; Shao Y.-Y.; TSUNG-HAO LIU; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-19T01:54:19Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.; TSUNG-HAO LIU; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-19T01:54:19Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; TSUNG-HAO LIU; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-18T02:02:23Z |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Lu L.-C.;Lee Y.-H.;Chang C.-J.;Chia-Tung Shun;Fang C.-Y.;Shao Y.-Y.;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; Lee Y.-H.; Chang C.-J.; CHIA-TUNG SHUN; Fang C.-Y.; Shao Y.-Y.; Liu T.-H.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-03-09T05:18:33Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:31Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:31Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Ying-Chun Shen; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-25T07:00:58Z |
Solving the deficit of cancer pain management skills by education programs
|
YU-YUN SHAO; Lin W.-Y.; Lin C.-P.; Lu L.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2021-02-19T06:52:27Z |
Solving the deficit of cancer pain management skills by education programs
|
Shao Y.-Y.;Lin W.-Y.;Lin C.-P.;Lu L.-C.;Chih-Hung Hsu; Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; Lu L.-C.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2021-02-18T02:33:48Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.;Shao Y.-Y.;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Chiun Hsu;Cheng A.-L.; Lu L.-C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T02:33:48Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.;Liu T.-H.;Chiun Hsu;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.; Shao Y.-Y.; Liu T.-H.; Chiun Hsu; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:39Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2020-10-07T08:50:38Z |
Solving the deficit of cancer pain management skills by education programs
|
WEN-YING LIN; Shao Y.-Y; Lin C.-P; Lu L.-C; Hsu C.-H. |
| 臺大學術典藏 |
2020-08-14T03:15:30Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; I-LUN SHIH; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-08-07T02:32:18Z |
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
|
Shao Y.-Y.; CHIH-HORNG WU; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-07-21T07:51:10Z |
A dengue vector surveillance by humrn population-stratified ovitrap survey for aedes (Diptera: Culicidae) adult and egollections in high dengue-risk areas of Taiwan
|
Wu, H.-H. et al.; TZAI-HUNG WEN; Wu, H.-H.; Wang, C.-Y.; Teng, H.-J.; Lin, C.; Lu, L.-C.; Jian, S.-W.; Chang, N.-T.; Wen, T.-H.; Wu, J.-W.; Liu, D.-P.; Lin, L.-J.; Norris, D.E.; Wu, H.-S. |
| 臺大學術典藏 |
2020-06-26T07:52:32Z |
Targeted Disruption in Mice of a Neural Stem Cell-Maintaining, KRAB-Zn Finger-Encoding Gene That Has Rapidly Evolved in the Human Lineage
|
Chien H.-C.;Hurng-Yi Wang;Su Y.-N.;Lai K.-Y.;Lu L.-C.;Chen P.-C.;Tsai S.-F.;Wu C.-I.;Hsieh W.-S.;Shen C.-K.J.; Chien H.-C.; HURNG-YI WANG; Su Y.-N.; Lai K.-Y.; Lu L.-C.; Chen P.-C.; Tsai S.-F.; Wu C.-I.; Hsieh W.-S.; Shen C.-K.J. |
| 臺大學術典藏 |
2020-04-28T07:25:26Z |
Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy
|
Shao Y.-Y. ;Lu L.-C. ;Cheng A.-L. ;Chih-Hung Hsu; Shao Y.-Y.; Lu L.-C.; Cheng A.-L.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2020-04-28T07:25:20Z |
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
|
Shao Y.-Y.;Wu C.-H.;Lu L.-C.;Chan S.-Y.;Ma Y.-Y.;Yen F.-C.;Chih-Hung Hsu;Cheng A.-L.; Shao Y.-Y.; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; CHIH-HUNG HSU; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:20Z |
Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy
|
Lu L.-C.;Shao Y.-Y.;Chan S.-Y.;Chih-Hung Hsu;Cheng A.-L.; Lu L.-C.; Shao Y.-Y.; Chan S.-Y.; CHIH-HUNG HSU; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:14Z |
Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study
|
Lu L.-C.;Chen P.-J.;Yeh Y.-C.;Chih-Hung Hsu;Chen H.-M.;Lai M.-S.;Shao Y.-Y.;Cheng A.-L.; Lu L.-C.; Chen P.-J.; Yeh Y.-C.; CHIH-HUNG HSU; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:11Z |
Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma
|
Cheng A.-L.; CHIH-HUNG HSU; Liang C.-W.; Chang C.-J.;Yang Y.-H.;Chiu C.-J.;Lu L.-C.;Liao C.-C.;Liang C.-W.;Chih-Hung Hsu;Cheng A.-L.; Chang C.-J.; Yang Y.-H.; Chiu C.-J.; Lu L.-C.; Liao C.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:13Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:13Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Cheng A.-L.; Yeh K.-H.; Chiun Hsu; Cheng W.-F.; Lin Y.-L.; Lu L.-C.; Shao Y.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:03Z |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
Lu L.-C.; Hsu C.-H.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy
|
YU-YUN SHAO; Lu L.-C.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
YU-YUN SHAO; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Yeh K.-H.; Cheng A.-L.; Lin Y.-L.; Hsu C.; Cheng W.-F.; Hsu C.-H.; YU-YUN SHAO; Lu L.-C. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma
|
Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.; Lu L.-C.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:16:08Z |
β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Lu L.-C.;Yu-Yun Shao;Lee Y.-H.;Hsieh M.-S.;Hsiao C.-H.;Lin H.-H.;Kao H.-F.;Ma Y.-Y.;Yen F.-C.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; YU-YUN SHAO; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C. |
| 臺大學術典藏 |
2020-04-10T12:16:07Z |
Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy
|
Lu L.-C.;Yu-Yun Shao;Chan S.-Y.;Hsu C.-H.;Cheng A.-L.; Lu L.-C.; YU-YUN SHAO; Chan S.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:06Z |
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
|
Yen F.-C.; Hsu C.-H.; Cheng A.-L.; YU-YUN SHAO; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yu-Yun Shao;Wu C.-H.;Lu L.-C.;Chan S.-Y.;Ma Y.-Y.;Yen F.-C.;Hsu C.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:03Z |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Chan S.-Y.; Shau W.-Y.; YU-YUN SHAO; Yu-Yun Shao;Shau W.-Y.;Chan S.-Y.;Lu L.-C.;Hsu C.-H.;Cheng A.-L.; Lu L.-C.; Hsu C.-H.; Cheng A.-L. |
